Nearly 300,000 people in England could soon be eligible for a new heart failure treatment after the National Institute for Health and Care Excellence recommended finerenone for adults with symptomatic chronic heart failure with preserved or mildly reduced ejection fraction.
The guidance, published in mid-July, marks a significant addition to NHS treatment options for a condition that affects many patients with ongoing symptoms and repeated hospital visits. NICE said the pill can be used alongside usual care to reduce the risk of unplanned admission to hospital, broadening access to a therapy that had already drawn attention for its impact on worsening heart failure events.
What the new guidance means for patients
According to the BMJ report on the decision, adding finerenone to standard care reduces the total number of worsening heart failure events, including urgent hospital visits and hospital stays, by about 18% compared with placebo. The treatment is intended for adults with symptomatic chronic heart failure with preserved or mildly reduced ejection fraction, a group for whom reducing deterioration and avoidable admissions is especially important.
The approval could matter well beyond specialist cardiology clinics, because it gives NHS teams another option to manage patients who remain vulnerable despite current treatment. It also signals continued movement in heart failure care toward therapies designed not only to treat symptoms but also to reduce pressure on hospitals.
A broader shift in NHS heart failure care
NICE also noted that finerenone may reduce the risk of death from a cardiovascular event such as a heart attack or stroke, or from other causes, although the BMJ reported that the evidence for this remains less certain than the data on admissions and worsening events. Even so, the recommendation adds to the growing list of newer medicines shaping long-term cardiovascular care across the NHS.
For clinicians, the decision offers another evidence-based option for a patient group that often needs ongoing monitoring, medication adjustments and close follow-up. For patients, it may mean fewer acute episodes and a lower likelihood of being admitted to hospital unexpectedly.
Why this decision stands out
The approval is notable because it addresses a common and clinically demanding form of heart failure, while aiming to ease the burden on both patients and services. In a health system where unplanned admissions remain a major concern, even modest reductions in worsening episodes can have practical value.
The NICE recommendation places finerenone firmly on the NHS treatment map and gives heart failure teams a new tool to consider as they work to improve outcomes for people living with persistent cardiovascular disease. The full impact will depend on how quickly services adopt the guidance and how many eligible patients are identified in routine care.
Source material for this report included BMJ coverage of the NICE decision and the BMJ article archive.
Photo source: AI-generated or edited image
